Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression

Journal of Neuropathology and Experimental Neurology

Volumn 55, Issue 7, 1996, Pages 822-831

  Reifenberger, Julia ^a   Ring, Gudrun U ^a   Gies, Ursula ^a   Cobbers, J M J Ludwig ^a   Oberstraß, Jürgen ^a   An, Han Xiang ^a   Niederacher, Dieter ^a   Wechsler, Wolfgang ^a   Reifenberger, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

EGFR amplification; Glioma; p53 mutation; progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 0029890378     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199607000-00007     Document Type: Article

References (54)

1. Russell D, Rubinstein LJ. Pathology of tumors of the nervous system. 5th Edition. London: Edward Arnold, 1989:83-95
2. Müller W, Afra D, Schröder R. Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas. Acta Neurochir 1977;37:75-91
3. Laws ER, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984;61:665-73
4. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: Is deferring treatment safe? Ann Neurol 1992;31:431-36
5. McCormack BM, Miller DC, Budzilovic GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery 1992;31:636-42
6. Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 1991;28:496-501
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
8. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21
9. Bögler O, Huang HJS, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995;15:308-27
10. Hayashi Y, Yamashita J, Yamaguchi K. Timing and role of p53 gene mutation in the recurrence of glioma. Biochem Biophys Res Commun 1991;180:1145-50
11. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-79
12. Chozick BS, Weicker ME, Pezzullo JC, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 1994;73:406-15
13. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum M, Cavenne W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992;355:846-47
14. Collins VP. Gene amplification in human gliomas. Glia 1995;15: 289-96
15. Kleihues P, Burger PC, Scheithauer B. Histological typing of tumours of the central nervous system. Berlin, New-York, Heidelberg: Springer-Verlag, 1993
16. Oberstraß J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP. Mutation of the von Hippel-Lindau tumor suppressor gene in capillary hemangioblastomas of the central nervous system. J Pathol 1996 (in press)
17. Rosenbauer V, Riesner D. Temperature-gradient gel electrophoresis - Thermodynamic analysis of nucleic acids and proteins in purified form and in cellular extracts. Biophys Chem 1987;26:235-46
18. An HX, Niederacher D, Beckmann MW, et al. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 1995;64:291-97
19. Neubauer A, Neubauer B, He M, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992;7:1019-25
20. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 1995;54:57-64
21. Reifenberger G. Immunhistochemie der Tumoren des Nervensystems. Berlin: Springer-Verlag, 1991:28-32
22. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8
23. Lübbe J, von Ammon K, Watanabe K, Hegi ME, Kleihues P. Familial brain tumor syndrome associated with p53 germline deletion of codon 236. Brain Pathol 1995;5:15-23
24. Jaros E, Perry RH, Adam L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992;66:373-85
25. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation. Am J Pathol 1993;142:1347-51
26. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumors: An immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 1993;85:611-16
27. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-38
28. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 1993;52:31-38
29. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 1993;3: 229-35
30. Kraus JA, Bolin C, Wolf HK, et al. p53 alterations and clinical outcome in low-grade astrocytomas. Genes Chrom Cancer 1994;10: 143-49
31. van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J Natl Cancer Inst 1994;86:1011-17
32. Bártek J, Bártková J, Vojtesek B, et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 1990;46:839-44
33. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of the p53 tumor suppressor gene protein is an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55
34. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-39
35. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: The role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16
36. Hall PA, Lane DP. p53 in tumor pathology: Can we trust immunohistochemistry? (revisited) J Pathol 1994;172:1-4
37. Rubio MP, von Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-67
38. Lang FL, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low-grade and anaplastic astrocytomas. Oncogene 1994;9:949-54
39. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in non-astrocytic human brain tumors. Cancer Res 1991;51:6202-5
40. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinogen 1993;8:74-80
41. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors show preferential allelic losses on chromosome arms 19q and 1p. Am J Pathol 1994;145:1175-90
42. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95
43. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10
44. Reifenberger J, Reifenberger G, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. (Abstract) Clin Neuropathol 1995;14:278
45. Burger PC, Green SB. Patient age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25
46. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989;71:487-93
47. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26
48. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81: 427-36
49. Leenstra S, Bijlsma EK, Troost D, et al. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 1994;70:684-89
50. Rasheed BKA, McLendon RE, Herndon JE, et al. Alterations of the Tp53 gene in human gliomas. Cancer Res 1994;54:1324-30
51. Louis DN, Rubio MP, Correa K, Gusella JF, von Deimling A. Molecular genetic alterations in pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol 1993;52:507-15
52. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-46
53. Van Meir EG, Polverini PJ, Chazin VR, Huang HJS, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994;8:171-76
54. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379:88-91